IPCA Laboratories Ltd
IPCALABIPCA Laboratories Ltd
IPCALABPrice Chart
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
66.19 | 4.94 | 0.27% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
49.79 | 6.29 | 0.52% |
Forecast & Ratings
Detailed Forecast from 15 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Ipca Laboratories Limited is engaged in pharmaceuticals business. The Company is a manufacturer and supplier of over 10 active pharmaceutical ingredients (APIs).
Peers
Compare with peersÂSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 2,889.33 | 3,168.94 | 3,299.56 | 3,803.37 | 4,686.03 | 5,482.83 | 5,896.36 | 6,369.94 | 7,897.82 | 8,381.47 | ||||||||||
Raw Materials | 1,032.55 | 1,115.71 | 1,101.28 | 1,355.15 | 1,820.25 | 1,923.09 | 2,144.50 | 2,205.84 | 2,706.39 | 6,982.43 | ||||||||||
Power & Fuel Cost | 141.67 | 151.00 | 161.92 | 176.50 | 201.22 | 207.10 | 242.12 | 283.74 | 333.97 | |||||||||||
Employee Cost | 625.58 | 695.98 | 735.88 | 787.40 | 921.23 | 1,013.57 | 1,177.39 | 1,287.64 | 1,708.43 | |||||||||||
Selling & Administrative Expenses | 532.58 | 596.75 | 598.72 | 524.85 | 545.44 | 575.16 | 641.87 | 704.69 | 853.53 | |||||||||||
Operating & Other expenses | 242.49 | 147.58 | 205.93 | 208.35 | 228.73 | 153.49 | 311.14 | 832.99 | 954.84 | |||||||||||
EBITDA | 314.46 | 461.92 | 495.83 | 751.12 | 969.16 | 1,610.42 | 1,379.34 | 1,055.04 | 1,340.66 | 1,399.04 | ||||||||||
Depreciation/Amortization | 163.26 | 172.95 | 177.73 | 182.42 | 210.50 | 209.17 | 232.42 | 261.56 | 357.24 | 386.86 | ||||||||||
PBIT | 151.20 | 288.97 | 318.10 | 568.70 | 758.66 | 1,401.25 | 1,146.92 | 793.48 | 983.42 | 1,012.18 | ||||||||||
Interest & Other Items | 34.56 | 26.91 | 27.57 | 22.24 | 19.77 | 12.27 | 11.20 | 48.19 | 140.75 | 130.94 | ||||||||||
PBT | 116.64 | 262.06 | 290.53 | 546.46 | 738.89 | 1,388.98 | 1,135.72 | 745.29 | 842.67 | 881.24 | ||||||||||
Taxes & Other Items | 23.50 | 67.52 | 51.11 | 101.63 | 132.57 | 248.97 | 251.64 | 273.97 | 295.32 | 304.47 | ||||||||||
Net Income | 93.14 | 194.54 | 239.42 | 444.83 | 606.32 | 1,140.01 | 884.08 | 471.32 | 547.35 | 576.77 | ||||||||||
EPS | 3.69 | 7.71 | 12.65 | 35.23 | 47.99 | 59.99 | 34.85 | 18.58 | 21.57 | 22.73 | ||||||||||
DPS | 0.00 | 0.50 | 1.00 | 3.00 | 5.00 | 4.00 | 4.00 | 4.00 | 4.00 | 2.00 | ||||||||||
Payout ratio | 0.00 | 0.06 | 0.08 | 0.09 | 0.10 | 0.07 | 0.11 | 0.22 | 0.19 | 0.09 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
IPCA Laboratories Ltd | 69.75 | 4.94 | 0.27% |
Sun Pharmaceutical Industries Ltd | 44.57 | 6.36 | 0.76% |
Cipla Ltd | 29.50 | 4.54 | 0.86% |
Torrent Pharmaceuticals Ltd | 63.68 | 15.38 | 0.90% |
Price Comparison
Compare IPCALAB with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Mutual Funds Holding Trend
Mutual Fund Holding
In last 3 months, mutual fund holding of the company has almost stayed constant
Top 5 Mutual Funds holding IPCA Laboratories Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
HDFC Mid-Cap Opportunities Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 6.5692% | Percentage of the fund’s portfolio invested in the stock 3.35% | Change in the portfolio weight of the stock over the last 3 months 0.52% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 5/79 (+3) |
Kotak Emerging Equity Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 3.8501% | Percentage of the fund’s portfolio invested in the stock 3.01% | Change in the portfolio weight of the stock over the last 3 months 0.64% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 45/75 (+3) |
DSP Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.8417% | Percentage of the fund’s portfolio invested in the stock 3.60% | Change in the portfolio weight of the stock over the last 3 months 0.23% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 1/64 (+1) |
Compare 3-month MF holding change on Screener
smallcases
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have IPCA Laboratories Ltd
Events
Dividend Trend
Dividend Yield
Current dividend yield is 0.27%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.66 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateAug 6, 2024
Dividend/Share
₹2.00
Ex DateEx Date
Aug 6, 2024
Cash Dividend
Ex DateEx DateNov 22, 2023
Dividend/Share
₹2.00
Ex DateEx Date
Nov 22, 2023
Cash Dividend
Ex DateEx DateNov 22, 2022
Dividend/Share
₹4.00
Ex DateEx Date
Nov 22, 2022
Cash Dividend
Ex DateEx DateNov 22, 2021
Dividend/Share
₹8.00
Ex DateEx Date
Nov 22, 2021
Cash Dividend
Ex DateEx DateNov 13, 2020
Dividend/Share
₹8.00
Ex DateEx Date
Nov 13, 2020
Ipca Laboratories will hold a meeting of the Board of Directors of the Company on 14 November 2024.Powered by Capital Market - Live
Ipca Laboratories has fixed 22 November 2024 as record date for payment of interim dividend that may be declared at the meeting of the Board of Directors of the Company scheduled to be held on 14 November 2024.Powered by Capital Market - Live
The domestic equity benchmarks pared all gains and traded with minor losses in morning trade. The Nifty traded below the 25,800 level. IT shares advanced after declining for the past trading sessions. At 10:30 ST, the barometer index, the S&P BSE Sensex, was down 3.32 points or 0.01% to 84,298.60. The Nifty 50 index fell 13.15 points or 0.05% to 25,794.15. In the broader market, the S&P BSE Mid-Cap index shed 0.12% and the S&P BSE Small-Cap index added 0.27%. The market breadth was strong. On the BSE, 2,265 shares rose and 1,324 shares fell. A total of 166 shares were unchanged. Due to the observance of Mahatma Gandhi Jayanti on Wednesday, 2 October 2024, the domestic market will be closed. Economy: India's fiscal deficit remained under control during April-August, reaching 27% of the full-year target. This containment was attributed to muted spending in the early months of the fiscal year. The government's spending has been lower due to general elections. In comparison, the deficit stood at a higher 36% during the same period in FY24. Buzzing Index: The Nifty IT index added 0.91% to 42,329.55. The index declined 0.87% in the past trading sessions. Tech Mahindra (up 3.16%), Infosys (up 1.53%), Wipro (up 1.1%), Mphasis (up 1.1%) and Coforge (up 0.91%), Persistent Systems (up 0.54%), HCL Technologies (up 0.08%), LTIMindtree (up 0.06%), L&T Technology Services (up 0.01%) edged higher. Stocks in Spotlight: India Glycols advanced 7.86% after the company has increased its grain-based distillery capacity by 100 KLPD at Kashipur, Uttarakhand and added 180 KLPD to its existing bio-fuel ethanol plant at the same location. Additionally, it has expected its facilities for new value-added chemicals products by 2500 MTPA in Kashipur, Uttarakhand. IPCA Laboratories fell 1.11% after the company's subsidiary, Bayshore will sell nine ANDAs to US-based Unichem for $2.65million, along with its generic business for $10 million.Powered by Capital Market - Live
The Board of Ipca Laboratories at its meeting held on 30 September 2024 has approved entering into the following agreements by Bayshore Pharmaceuticals LLC, USA (Bayshore) (wholly-owned step down subsidiary) with Unichem Laboratories (Unichem India) (subsidiary company) and Unichem Pharmaceuticals (USA) Inc (Unichem USA) (wholly owned subsidiary of Unichem India), so as to integrate and consolidate all the Ipca Group's USA generic formulations business under one entity: a) Sale of all rights, title and interest in the product approvals and all goodwill associated with nine (9) ANDAs owned by Bayshore for US Dollar Two Million Six Hundred Fifty Thousand ($2,650,000) through asset sale agreement subject to necessary consents/ approvals to Unichem India; and b) Sale of all generic formulations marketing / distribution business of Bayshore in the US market as a going concern through slump sale/transfer of entire business (debt free) and all goodwill associated with the business through business sale agreement for US Dollar Ten Millions ($10,000,000) to Unichem USA.Powered by Capital Market - Live
Ipca Laboratories will hold a meeting of the Board of Directors of the Company on 30 September 2024.Powered by Capital Market - Live
Ipca Laboratories Ltd is up for a third straight session today. The stock is quoting at Rs 1457, up 3.16% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.06% on the day, quoting at 25182.65. The Sensex is at 82274.5, down 0.09%. Ipca Laboratories Ltd has gained around 10.43% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has gained around 8.25% in last one month and is currently quoting at 23184.4, up 0.68% on the day. The volume in the stock stood at 10.05 lakh shares today, compared to the daily average of 5.44 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 1461.2, up 3.01% on the day. Ipca Laboratories Ltd is up 62.35% in last one year as compared to a 28.41% jump in NIFTY and a 52.01% jump in the Nifty Pharma index.The PE of the stock is 58.06 based on TTM earnings ending June 24.Powered by Capital Market - Live
Ipca Laboratories Ltd rose for a third straight session today. The stock is quoting at Rs 1416.1, up 2.3% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.12% on the day, quoting at 24728.5. The Sensex is at 80764.15, down 0.05%. Ipca Laboratories Ltd has added around 16.67% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has added around 9.29% in last one month and is currently quoting at 22374.25, up 0.83% on the day. The volume in the stock stood at 6.38 lakh shares today, compared to the daily average of 5.41 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 1418, up 2.58% on the day. Ipca Laboratories Ltd is up 60.02% in last one year as compared to a 27.49% gain in NIFTY and a 47.43% gain in the Nifty Pharma index.The PE of the stock is 57.01 based on TTM earnings ending June 24.Powered by Capital Market - Live
Net profit of Ipca Laboratories rose 18.07% to Rs 192.24 crore in the quarter ended June 2024 as against Rs 162.82 crore during the previous quarter ended June 2023. Sales rose 32.01% to Rs 2092.63 crore in the quarter ended June 2024 as against Rs 1585.21 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales2092.631585.21 32 OPM %18.7719.41 - PBDT389.28321.09 21 PBT290.39251.82 15 NP192.24162.82 18 Powered by Capital Market - Live
Ipca Laboratories Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 1378.5, up 0.94% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.24% on the day, quoting at 24427.1. The Sensex is at 79938.07, up 0.29%. Ipca Laboratories Ltd has risen around 12.3% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has risen around 6.42% in last one month and is currently quoting at 22209.55, down 0.12% on the day. The volume in the stock stood at 2.55 lakh shares today, compared to the daily average of 4.36 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 1374.65, up 0.59% on the day. Ipca Laboratories Ltd is up 55.86% in last one year as compared to a 25.69% spurt in NIFTY and a 44.93% spurt in the Nifty Pharma index.The PE of the stock is 57.68 based on TTM earnings ending March 24.Powered by Capital Market - Live
Ipca Laboratories Ltd is up for a third straight session in a row. The stock is quoting at Rs 1368.65, up 2.1% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.12% on the day, quoting at 24269.55. The Sensex is at 79387.27, down 0.1%. Ipca Laboratories Ltd has risen around 12.12% in last one month. Meanwhile, Nifty Pharma index of which Ipca Laboratories Ltd is a constituent, has risen around 7.67% in last one month and is currently quoting at 22036.95, up 0.88% on the day. The volume in the stock stood at 4.13 lakh shares today, compared to the daily average of 4.08 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 1370, up 1.84% on the day. Ipca Laboratories Ltd is up 50.09% in last one year as compared to a 23.62% spurt in NIFTY and a 41.62% spurt in the Nifty Pharma index.The PE of the stock is 56.72 based on TTM earnings ending March 24.Powered by Capital Market - Live
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 15.74%, vs industry avg of 9.03%
Increasing Market Share
Over the last 5 years, market share increased from 1.73% to 2.09%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 4.24%, vs industry avg of 15.28%